Morgan Stanley downgraded Demant (WILYY) to Equal Weight from Overweight with a price target of DKK 221, down from DKK 250. The firm says macro headwinds continue to present earnings risk for medical technology services in 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WILYY: